Switzerland’s Galderma today announced that the European Commission has approved Nemluvio for both moderate-to-severe atopic ...

Nemluvio, which was also approved for prurigo nodularis, becomes Galderma’s first approved biologic in its dermatology ...

Galderma (SWX:GALD) today announced that the European Commission has approved Nemluvio for both moderate-to-severe atopic dermatitis and prurigo nodularis in the European Union (EU). Nemluvio is now ...

Ad hoc announcement pursuant to Art. 53 LR This approval from the European Commission is based on robust results from the phase III OLYMPIA and ...

Incyte’s ruxolitinib franchise, made up of blockbuster JAK inhibitor Jakafi and its topical counterpart Opzelura, have been ...

Enrollment of Part A completed ahead of schedule and exceeded enrollment target with 123 patients enrolledPart A 16-week proof-of-concept data ...

2024 was a big year for the atopic dermatitis (AD) treatment landscape ... first got approved in the Japanese market for its association with AD and then for prurigo nodularis in adults. Now we have ...

In addition to receiving the randomized treatment, all participants in the ... controlled trials in 874 participants with moderate to severe acute pain following abdominoplasty and bunionectomy ...

As a teenager, my doctor said it was the most severe case she’d ever seen ... 1.Q: What are your symptoms, and what causes them to flare up? A: I have a lot of tics, but my main ones are ...

Prurigo nodularis (PN) is a chronic inflammatory skin disease which presents as a persistent solitary pruritic hard papules and nodules. Dupilumab has been approved by the Food and Drug Administration ...